ASH Clinical News Focus on Myeloid Malignancies | Page 10

IN THE PIPELINE
The Myeloid Malignancies Pipeline
Below is a list of agents currently under investigation for
the treatment of myeloid malignancies, including acute
myeloid leukemia (AML), chronic myeloid leukemia (CML),
myeloproliferative neoplasms (MPN), myelodysplastic
syndromes (MDS), blastic plasmacytoid dendritic cell
neoplasm (BPDCN), and MDS/MPN overlap syndromes,
including chronic myelomonocytic leukemia (CMML).
Information was gathered from ClinicalTrials.gov, as well
as the respective drug manufacturers. For a comprehensive
list of agents being evaluated for these conditions, please
consult ClinicalTrials.gov.
Monoclonal Antibodies
Vadastuximab talirine: a CD33-directed antibody-drug
conjugate for the treatment of treatment-naïve MDS (phase I/II)
and AML (phase III)
Iomab-B: a CD45-targeting radioisotope-conjugate